Search icon
TCS, HDFCBANK, SBI Liquid Fund (G)
Bafna Pharmaceuticals Ltd.

Bafna Pharma

NSE

0.00

0.00 (0.00)%

Healthcare

Small-cap

With a market cap of ₹18.90L Cr.

Moderate Volatility
Stock is 1.13x as volatile as index
To access realtime data for Reliance Industries Ltd, and use advance features for trading Register or Login to Orca.

Subsidiaries

No Data Available

No Subsidiaries Data available

Management

1. Vinayak Dinesh Dendukuri
Whole Time Director - Quality
2. Upendar Mekala Reddy
Non Independent & Non Executive Director
3. P K Sundaresan
Non Executive Independent Director
4. R Chitra
Non Executive Independent Director
5. Krishna Yeachuri
Non Executive Independent Director
6. A Mohanachandran
Company Secretary & Compliance Officer
7. Akila Chintalapati Raju
Non Independent & Non Executive Director
8. Shanmugam Hemalatha
Whole Time Director

Contact Information

Company Address

Bafna Towers, New No 68, Old No.299, Thambu Chetty Street
Chennai, Tamil Nadu - 600001
www.bafnapharma.com
info@bafnapharma.com

Registrar

Cameo Corporate Services Ltd
Subramanian Buildings No 1 , Club House Road,,Chennai
Phone: 044-28460390/28460394
Email:
Website:

Company Profile

Bafna Pharmaceuticals was incepted by Bafna Mahaveer Chand in 1981 as a proprietary concern. It was converted into a public limited company on 28th march 1995. The company started its own manufacturing unit in October 1984.

Bafna Pharmaceuticals started its production with tablets facility and subsequently added capsule and oral syrup facilities respectively. BAFNA always focused on institutional and generic supply to keep its production line busy. It also concentrated on registering its products in the international market.

The present manufacturing facilities of BAFNA is set up at Chennai. The facility for producing Betalactam products was constructed in the year 2001 in a separate block.

It acquired 2.65 acres of factory land in Grantylon village, near Chennai to expand its operations to regulated market like US and UK and also to manufacture its own products.

The company’s vision is to become a leading professionally run global pharma company setting standards across the pharma value chain.

Product Range:

  • Antibacterials
  • Antipyretics
  • Antconvulsants
  • Anxiolytics
  • Pain management
  • Anthelmintics
  • Antifungal
  • Appetite stimulants
  • Antidiarrhoeals
  • Antiemetics
  • Hypnotics
  • Antacids and antiulcerants
  • Vitamin and dietery preparation
  • Cough and cold preparations
  • Antiasthmatics
  • Calcium preparations
  • Antihypertensives
  • Antidiabetics

Achievements/ Awards:

  • BAFNA was awarded the WHO GMP in the year 1995.
  • Bagged the ‘Best Supplier Award’ from the State Pharmaceutical Corporation of Sri Lanka on 30th July 2005.
  • Accorded the status of an ‘Export House’ in recognition of its excellent export performance.
  • Received Medicines and Health Care Products Regulatory Agency (MHRA) approval for its Grantlyon facility meant for exports to the UK markets. Bafna was the 35th company in the Indian pharmaceuticals industry (IPI) to receive MHRA approval.
  • 2009 ISO 9001: 2000 Certificate of Registration for Manufacture and Export of Pharmaceutical products
  • MHRA Certificate of GMP Compliances of Manufacturer from Medicines and Healthcare products Regulatory Agency, U.K.
  • 2010 Bafna Pharmaceuticals have been awarded the Gold Quality Excellence Award 2009
  • Bafna Pharmaceuticals have inaugurated its Formulation Research & Development unit (Formulation Facility) in Chennai
  • 2011 Bafna Pharmaceuticals has received Indian Drug Manufacturer's Association (IDMA) Quality Excellence Award 2010 - Silver Award under the category of Formulations Units
  • Bafna Pharmaceuticals has received Udyog Rattan Award and Excellence Award from the Institute of Economic Studies Delhi.
Enrich money logo